Epizyme initiates pediatric MLL-r proof-of-concept study for leukemia candidate Epizyme initiated a Phase 1b open-label clinical study of EPZ-5676 in pediatric patients with acute leukemias bearing a rearrangement of the MLL gene. This Phase 1b study is designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of escalating doses of EPZ-5676 in patients between the ages of 3 months and 18 years and to provide a preliminary assessment of efficacy. Expected data disclosure date is in 2H14.
Epizyme announces presentation of EPZ-6438, EPZ-5676 data Epizyme announced that clinical and pre-clinical data on its histone methyltransferase inhibitors will be highlighted in oral and poster presentations at the 56th annual meeting of the American Society of Hematology to be held December 6-9 in San Francisco, California. The company will present data from EPZ-5676 and EPZ-6438 studies.